Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Oncology and Cancer Research
Metadata
Title
B7-H4 expression and increased death risk of cancer patients: A meta-analysis
Authors
Jing-ting Jiang
Chang-ping Wu
Xiao Zheng
Yao Zhao
Bin Xu
Bin-feng Lu
Yue-ping Shen
Publication date
01-12-2011
Publisher
Tianjin Medical University Cancer Institute and Hospital
Published in
Clinical Oncology and Cancer Research / Issue 4/2011
Print ISSN: 1674-5361
Electronic ISSN: 1868-324X
DOI
https://doi.org/10.1007/s11805-011-0586-4

Other articles of this Issue 4/2011

Clinical Oncology and Cancer Research 4/2011 Go to the issue

OriginalPaper

Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer

OriginalPaper

Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer

OriginalPaper

Changing paradigms in clinical oncology research — Highlights from the 2011 ASCO annual meeting and beyond

OriginalPaper

Expression of the B-cell lymphoma/leukemia 11A gene in malignant hematological cell lines through quantitative reverse transcription polymerase chain reaction

OriginalPaper

Gastric diffuse large B-cell lymphoma after the diagnosis of primary MALT lymphoma of the breast—One case report

OriginalPaper

Monoclonal antibodies in cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits